Hengrui announces new drug SHR7280
On October 11, 2021, Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that SHR0302, for the treatment of mild to moderate atopic dermatitis Phase II/III seamless adaptive design clinical study RSJ10431 (MARBLE23), phase II clinical study Reach the effective end point preset in the plan. This is following the clinical studies of atopic dermatitis phase II (QUARTZ2), ulcerative colitis phase II (AMBER2), and alopecia areata phase II (CRYSTAL2) of oral tablets in October 2020, February 2021 and 2021, respectively. A positive result was obtained in August.
In January 2021, CDE awarded the title of Oral SHR0302 Breakthrough Therapy.
Atopic dermatitis is a serious chronic inflammatory skin disease that affects 1% to 3% of adults and 15% to 20% of children worldwide. The main manifestations are intense itching, obvious eczema-like changes and dry skin. Inhibition of the JAK1 signaling pathway is believed to regulate multiple signaling pathways related to the pathogenesis of specific dermatitis, including IL-4, IL-13, IL-31 and interferon γ.